Antinuclear antibodies seroconversion and endoscopic response to infliximab in biologic-naive Crohn’s disease: a Chinese single-center, retrospective study
ANA non-seroconversion at 6 months was associated with higher rates of endoscopic remission and a lower likelihood of developing antibodies against infliximab.
Authors
- Juntao Lu
- Jun Shen (ORCID: https://orcid.org/0000-0001-7746-5285)
- Zhanghan Dai
- Yuan Cao (ORCID: https://orcid.org/0000-0002-4632-9990)
- Zhijun Cao (ORCID: https://orcid.org/0000-0002-5519-9462)
- Jinlu Tong
- Tianrong Wang
- Ying Sun (ORCID: https://orcid.org/0000-0002-2042-6514)
- Xitao Xu (ORCID: https://orcid.org/0009-0005-8984-1264)
- Yuqi Qiao
- Mingming Zhu (ORCID: https://orcid.org/0000-0002-5978-4992)
Institutions
- Second Military Medical University (CN)
- Renji Hospital (CN)
- Shanghai Institute of Hematology (CN)
- Shanghai Pudong New Area Gongli Hospital (CN)
Publication Details
- Journal
- Intestinal Research
- Published
- 2025-11-14
- DOI
- https://doi.org/10.5217/ir.2025.00018
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00